Pharmaceuticals India

India Celiac Disease Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

India Celiac Disease Treatment Market Industry Trends and Forecast to 2034: Segmented by (Approach, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

India · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $17.3 Mn Placeholder estimate
Estimate 2025 $19.5 Mn 2% of the global market
Projected 2034 $55.7 Mn 186.3% Adds $36.3 Mn over 9 forecast years
CAGR 2025–2034 12.4% Faster than 59% of 180 Pharmaceuticals markets here
Key players 5
  • India is 2.05% of the global market.
  • In APAC, the largest is China at $88.3 Mn.
  • Fastest growing: India (this report) at 12.4% a year.
  • India ranks 3rd of 10 by size in APAC.

Market size projection

India

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$36.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Celiac Disease Treatment Market market size by year, India
YearMarket sizeChange that yearSince 2025
2024 (estimate) $17.3 Mn — —
2025 (base) $19.5 Mn +$2.1 Mn —
2026 (forecast) $21.9 Mn +$2.4 Mn +12.4%
2027 (forecast) $24.6 Mn +$2.7 Mn +26.3%
2028 (forecast) $27.6 Mn +$3.0 Mn +42%
2029 (forecast) $31.1 Mn +$3.4 Mn +59.6%
2030 (forecast) $34.9 Mn +$3.9 Mn +79.4%
2031 (forecast) $39.2 Mn +$4.3 Mn +101.6%
2032 (forecast) $44.1 Mn +$4.9 Mn +126.7%
2033 (forecast) $49.6 Mn +$5.5 Mn +154.8%
2034 (forecast) $55.7 Mn +$6.1 Mn +186.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

India Celiac Disease Treatment Market Analysis at a glance
Market size, 2025$19.5 Mn placeholder estimate
Forecast, 2034$55.7 Mn placeholder estimate
Growth (CAGR), 2025–203412.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsApproach, age and end user (see all)
Key playersTakeda Pharmaceutical Company Ltd, Anokion, Teva Pharmaceutical, ImmunogenX, Dr. Schar (see all)
Regulator in IndiaCDSCOSource: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The India Celiac Disease Treatment Market Analysis Executive Summary

Celiac disease treatment today is a gluten-free diet, with new medicines in development to protect the gut from gluten.

Key segments of the celiac Disease Treatment market include approach (Gluten-Free Diet Products, Enzyme Therapies and Tolerance Therapies) and age (Children and Adults).

Bar chart: India Celiac Disease Treatment market size, 2024–2034, placeholder estimates. $17.3 Mn in 2024, $19.5 Mn in 2025 and $55.7 Mn in 2034, 12.4% CAGR.
India Celiac Disease Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

India Celiac Disease Treatment Market Dynamics

Market Growth Drivers

More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the celiac Disease Treatment market. Biosimilars are widening access.

Opportunity

New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the celiac Disease Treatment market room to grow.

Market Restraints

High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the celiac Disease Treatment market.

Competitive Landscape for Celiac Disease Treatment Market in India

The celiac Disease Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Celiac Disease Treatment Market in India

Celiac Disease Treatment in India: rules and payment

New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India.⁠[1] Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year.⁠[2]

[1] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[2] National Health Authority (PM-JAY). Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for celiac Disease Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in India.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Celiac Disease Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Celiac Disease Treatment in context

India compared

  • Health spending per person: 85 US$ per person (2023). World: 1,317 US$ per person (2023). 10th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 0.72 per 1,000 people (2020). World: 1.86 per 1,000 people (2022). 11th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 7.4% of people (2025). World: 10.4% of people (2025). 11th highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Celiac Disease Treatment market in India?
Placeholder estimate: about $19.5 Mn in 2025, rising to about $55.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Celiac Disease Treatment market in India growing?
Placeholder estimate: about 12.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Celiac Disease Treatment market report cover?
The report splits the market by approach (Gluten-Free Diet Products, Enzyme Therapies, Tolerance Therapies, Diagnostics), age (Children, Adults) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Celiac Disease Treatment market?
Key players include Takeda Pharmaceutical Company Ltd, Anokion, Teva Pharmaceutical, ImmunogenX and Dr. Schar.
What is driving the Celiac Disease Treatment market?
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the celiac Disease Treatment market. Biosimilars are widening access.
Who regulates Celiac Disease Treatment in India?
New drugs and clinical trials need approval from the Central Drugs Standard Control Organisation (CDSCO), headed by the Drugs Controller General of India. Source: Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
How is healthcare paid for in India?
Ayushman Bharat PM-JAY gives eligible families hospital cover of up to ₹5 lakh a year. Source: National Health Authority (PM-JAY). Checked 14 Nov 2026.
How much research is published on Celiac Disease Treatment?
PubMed lists 1,496 papers on Celiac Disease Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in India

See all

Related on autoimmune diseases and gut health

See the topic